Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure
暂无分享,去创建一个
P. Tsao | J. Spin | V. Rudolph | S. Baldus | T. Rudolph | Matti Adam | U. Radunski | S. Meyer | A. Klinke | A. Costard-Jäckle | Henning Knors
[1] Marta Elena Losa-Iglesias,et al. Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.
[2] L. Holzhauser,et al. Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening , 2014, Heart Failure Reviews.
[3] M. Volpe,et al. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. , 2013, Journal of hypertension.
[4] M. Aslan,et al. Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome , 2013, Redox report : communications in free radical research.
[5] M. Sperandio,et al. Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. , 2013, Antioxidants & redox signaling.
[6] A. Parkhomenko,et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. , 2012, International journal of cardiology.
[7] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[8] Jiaquan Xu,et al. Deaths: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[9] M. Joannidis,et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study , 2011, Critical care.
[10] C. Detter,et al. Myeloperoxidase deficiency preserves vasomotor function in humans , 2011, European heart journal.
[11] M. Sperandio,et al. Myeloperoxidase attracts neutrophils by physical forces. , 2011, Blood.
[12] A. Buser,et al. Use of myeloperoxidase for risk stratification in acute heart failure. , 2010, Clinical chemistry.
[13] A. Cohen-Solal,et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. , 2009, Journal of the American College of Cardiology.
[14] F. Uberti,et al. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel , 2009, British journal of pharmacology.
[15] G. Filippatos,et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart , 2008, Expert opinion on investigational drugs.
[16] D. Hu,et al. Pulse Pressure and Mean Arterial Pressure in Relation to Ischemic Stroke Among Patients With Uncontrolled Hypertension in Rural Areas of China , 2008, Stroke.
[17] G. Filippatos,et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. , 2008, Atherosclerosis.
[18] M. Gheorghiade,et al. Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation , 2008, European journal of heart failure.
[19] G. Filippatos,et al. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. , 2007, Atherosclerosis.
[20] R. Schnabel,et al. Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. , 2007, Free radical biology & medicine.
[21] A. Hoes,et al. Clinical epidemiology of heart failure , 2007, Heart.
[22] S. Hazen,et al. Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.
[23] G. Filippatos,et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. , 2006, The American journal of cardiology.
[24] C. Abrass,et al. Levosimendan protects against experimental endotoxemic acute renal failure. , 2006, American journal of physiology. Renal physiology.
[25] H. Klemm,et al. Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase , 2006, Circulation.
[26] I. Kallikazaros,et al. The Ca2+‐sensitizer levosimendan improves oxidative damage, BNP and pro‐inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine , 2005, European journal of heart failure.
[27] M. Safar,et al. Vascular Development, Pulse Pressure, and the Mechanisms of Hypertension , 2005, Hypertension.
[28] L. Pączek,et al. Lack of relationship between interleukin-6 and CRP levels in healthy male athletes. , 2005, Immunology letters.
[29] T. Meinertz,et al. Systemic Endothelial Dysfunction as an Early Predictor of Adverse Outcome in Heart Failure , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[30] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[31] Stuart D Katz,et al. Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.
[32] M. Kuo,et al. beta-Lapachone reduces endotoxin-induced macrophage activation and lung edema and mortality. , 2003, American journal of respiratory and critical care medicine.
[33] K. Chayama,et al. Circadian variation of blood pressure and endothelial function in patients with essential hypertension:a comparison of dippers and non-dippers. , 2002, Journal of the American College of Cardiology.
[34] J. Cleland,et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.
[35] Chunxiang Zhang,et al. Myeloperoxidase, a Leukocyte-Derived Vascular NO Oxidase , 2002, Science.
[36] T. Rassaf,et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[37] K. Kataoka,et al. Serial circulating concentrations of c‐reactive protein, interleukin (il)‐4, and il‐6 in patients with acute left heart decompensation , 1999, Clinical cardiology.
[38] M. Moskowitz,et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.
[39] A. Ogata,et al. Hypoxic stress induces cardiac myocyte-derived interleukin-6. , 1995, Circulation.
[40] MA Moskowltz,et al. Clinical epidemiology , 2008, Journal of General Internal Medicine.
[41] D. Kereiakes,et al. Endothelial dysfunction. , 2003, Circulation.
[42] E. Porteri,et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. , 1998, Hypertension.